AAV Gene Delivery of TERT and Klotho for Age-Related Cognitive Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches are inefficient in delivering therapeutic genes to target cells for treating complex conditions like dementia, which is characterized by multifaceted biological causes and symptoms, and there are no effective treatments to slow or prevent age-related cognitive decline.
Innovation Solution
Administration of recombinant viral vectors encoding the human telomerase reverse transcriptase (TERT) and human klotho (KL) genes using adenovirus-associated virus (AAV) vectors, particularly serotypes AAV8 and AAV9, to the central nervous system via intranasal or intrathecal routes, with optional pre-treatment of nasal mucosa with hyaluronidase, to enhance gene delivery and expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional viral vectors (retroviral, adenoviral) are used for gene delivery, then gene delivery efficiency is improved, but immunological side effects and toxicity increase
Solution Approach 1:
The patent changes the vector type parameter from conventional retroviral or adenoviral vectors to adeno-associated viral (AAV) vectors, which have different biological properties including lower immunogenicity and toxicity while maintaining gene delivery efficiency. This parameter change resolves the contradiction by selecting a vector system with fundamentally different safety characteristics.
2Adaptability or versatility
If gene therapy is applied to complex conditions like dementia, then treatment scope is expanded, but treatment effectiveness decreases due to multifaceted biological causes
Solution Approach 1:
The patent segments the complex dementia condition into specific targetable pathways by selecting and delivering individual therapeutic genes (TERT, KL, SIRT1, FOXO3A, BDNF) that address specific biological mechanisms. This segmentation approach allows targeted intervention in specific pathological processes rather than attempting to treat the entire complex condition simultaneously, thereby improving treatment effectiveness.
Solution Approach 2:
The patent applies local quality by delivering specific therapeutic genes to specific target cells or tissues involved in dementia pathology. Each gene therapy construct is designed to address specific local pathological features of dementia, such as neuronal damage, oxidative stress, or inflammation in particular brain regions, rather than attempting uniform treatment of the entire system.
3Productivity
If viral vectors are produced in clinically significant quantities, then manufacturing scalability is improved, but vector purity and quality control become more difficult
Solution Approach 1:
The patent uses intermediary elements such as selectable markers, reporter genes, and purification tags incorporated into the AAV vector construction to facilitate quality control during large-scale manufacturing. These intermediary components enable detection, selection, and purification of correct vector particles, maintaining manufacturing precision even at clinical production scales.
Data Source
AI summary
Disclosed herein are methods for treating or prophylactically treating age-related cognitive decline associated with dementia by administering recombinant viral vectors designed to deliver TERT and/or KL (Klotho) genes to the patient. The TERT and/or KL genes are packaged within one or more AAV viral vectors and administered to the CNS of the patient via intranasal and/or intrathecal injection. The therapy can provide improvements in cognitive function as evidenced by improved Folstein/MMSE scores over time.